ArticleJournal of translational autoimmunity2026
Soluble immune checkpoints reflect immune activation and treatment response in high-risk systemic sclerosis patients treated with plasma exchange.
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic sclerosis (SSc) is an autoimmune disease characterized by immune dysregulation, vasculopathy, and fibrosis. High-risk patients, particularly those with diffuse cutaneous involvement (dcSSc) and interstitial lung disease (ILD), may benefit from early intensive immunosuppressive therapy during the inflammatory phase of the disease. We hypothesized that soluble immune checkpoints (sICPs) reflect immune activation and serve as biomarkers for disease activity and treatment response. Methods: Plasma levels of 15 sICPs (including sPD-1, sTIM-3, sBTLA, sCD25, sCD137, sIDO), cytokines, B cell activating factor (BAFF) and dephosphorylated-uncarboxylated Matrix Gla Protein (dp-ucMGP) were analyzed in a prospective SSc cohort (n = 35). A high-risk subset (n = 14) received an intensified immunosuppressive regimen consisting of therapeutic plasma exchange (TPE), cyclophosphamide, and maintenance therapy with mycophenolate mofetil or rituximab in cases of intolerance. Samples were obtained at baseline, 6, and 12 months. Correlations with clinical variables and treatment response were assessed using non-parametric statistics and principal component analysis (PCA). Findings: Patients selected for intensified treatment had a distinct inflammatory profile with elevated levels of sICPs and BAFF, while CRP levels did not differ. sICPs correlated positively with dp-ucMGP, indicating a link between vascular dysfunction and immune activation. Classical pro-inflammatory cytokines (e.g., IL-6, TNFα), however, showed weak correlations with disease severity. Longitudinal analysis showed a significant decline in most sICPs within 6 months of treatment, whereas cytokine levels remained stable. Survival and pulmonary function were preserved during a median follow-up of 4.5 years. Interpretation: sICPs reflect T cell dysregulation and disease severity in SSc more accurately than classical cytokines. Early intervention in inflammatory, high-risk patients may prevent long-term clinical deterioration. The observed decline of sICPs following treatment supports their potential as early biomarkers of treatment response. Moreover, the correlation between sICPs and dp-ucMGP suggests a mechanistic link between vascular and immune pathology in SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.